Betta Pharmaceuticals Co., Ltd.

贝达药业股份有限公司

Fully integrated commercial-stage biopharmaceutical company in China developing and commercializing innovative oncology drugs, with nine marketed products including targeted lung cancer therapies (icotinib, ensartinib, vorolanib) and a pipeline of over ten clinical programs.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Leased property
• Social insurance & housing fund
• Customer concentration
• Supplier concentration
• Connected or related major customers / suppliers
• Distribution model
• Reliance on platforms, partners or licences
• Pricing policy and price changes
• Outsourced production (OEM / contract manufacturing)
• Key long-term agreements
• Decline in revenue or profit
• Net current liabilities or net liabilities
• Working capital: receivables, prepayments and cash cycle
• Inventory level and ageing
• Goodwill, intangibles and asset impairment
• Investments and fair-value assets
• Non-IFRS measures and adjustments